These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10730148)

  • 1. [The 5q(-) syndrome. Report of 2 cases].
    Ben Lakhal R; Meddeb B; Gouider E; Aissaoui L; Sannana Sandi H; Ben Abid H; Belhaj Ali Z; Hafsia R; Hafsia A
    Tunis Med; 1999 Nov; 77(11):589-92. PubMed ID: 10730148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report.
    Znoyko I; Stuart RK; Ellingham T; Winters J; Wolff DJ; Quigley DI
    Cancer Genet Cytogenet; 2008 May; 183(1):64-8. PubMed ID: 18474300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
    Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears.
    Bigoni R; Cuneo A; Milani R; Cavazzini F; Bardi A; Roberti MG; Agostini P; della Porta M; Specchia G; Rigolin GM; Castoldi G
    Haematologica; 2001 Apr; 86(4):375-81. PubMed ID: 11325642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic analysis in patients with myelodysplastic syndrome.
    Hu N; Bian M
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(3):135-9. PubMed ID: 2098765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
    Beyer V; Castagné C; Mühlematter D; Parlier V; Gmür J; Hess U; Kovacsovics T; Meyer-Monard S; Tichelli A; Tobler A; Jacky E; Schanz U; Bargetzi M; Hagemeijer A; de Witte T; van Melle G; Jotterand M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):29-41. PubMed ID: 15193439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trisomy 14 in myelodysplastic syndromes: report of two cases and review of the literature.
    Vasef MA; Murata-Collins JL; Alsabeh R; Medeiros LJ
    Arch Pathol Lab Med; 1998 Jan; 122(1):77-83. PubMed ID: 9448022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
    Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Fidler C; Cazzola M; Hellström-Lindberg E; Wainscoat JS
    Br J Haematol; 2007 Nov; 139(4):578-89. PubMed ID: 17916100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chromosomal aberrations in myelodysplastic syndrome].
    Ol'shanskaia IuV; Domracheva EV; Udovichenko AI; Vodinskaia LA; Zakharova AV; Parovichnikova EN; Tsvetaeva NV; Mikhaĭlova EA; Glasko EN; Kolosova LIu; Kokhno AN; Tikhonova LIu; Shitareva TV; Smirnova EA; Alimova GA; Shirin AD; Vinogradova OIu; Khoroshko ND; Savchenko VG
    Ter Arkh; 2005; 77(7):27-33. PubMed ID: 16116905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
    Eclache V; Da Rocha A; Le Roux G; Fenaux P
    Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The 5q- syndrome associated with marked erythroid hypoplasia and Coombs test positive hemolysis].
    Ohno T; Hishizawa M; Sugiyama T; Mizumoto T; Furukawa H
    Rinsho Ketsueki; 1999 Jun; 40(6):499-504. PubMed ID: 10422288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
    Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
    Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trisomy 4 and ring chromosome in a patient with acute myelomonocytic leukemia.
    Vicari L; Sebastio L; Stanziola MC; Fasanaro A; Ferrara F
    Haematologica; 1994; 79(1):83-5. PubMed ID: 15378955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5q- syndrome in a child with slowly progressive pancytopenia: a case report and review of the literature.
    Pitman SD; Victorio A; Rowsell E; Morris J; Wang J
    J Pediatr Hematol Oncol; 2006 Mar; 28(3):115-9. PubMed ID: 16679931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
    Wang L; Fidler C; Nadig N; Giagounidis A; Della Porta MG; Malcovati L; Killick S; Gattermann N; Aul C; Boultwood J; Wainscoat JS
    Haematologica; 2008 Jul; 93(7):994-1000. PubMed ID: 18508791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Leuk Res; 2007 Apr; 31(4):427-34. PubMed ID: 17161457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.